J
Jerry L. Spivak
Researcher at Johns Hopkins University School of Medicine
Publications - 172
Citations - 8698
Jerry L. Spivak is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Erythropoietin & Polycythemia vera. The author has an hindex of 45, co-authored 169 publications receiving 8419 citations. Previous affiliations of Jerry L. Spivak include New York State Department of Health & Northwestern University.
Papers
More filters
Journal ArticleDOI
Decreased erythropoietin response in patients with the anemia of cancer.
TL;DR: It is concluded that erythropoietin levels are inappropriately low in anemia associated with cancer, and that eriespheric deficiency may contribute to the development of this form of anemia.
Journal ArticleDOI
Polycythemia vera: myths, mechanisms, and management.
TL;DR: Polycythemia vera is a clonal disorder arising in a multipotent hematopoietic progenitor cell that causes the accumulation of morphologically normal red cells, white cells, platelets, and their progenitors in the absence of a definable stimulus.
Journal ArticleDOI
Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders
Zhaohui Ye,Huichun Zhan,Prashant Mali,Prashant Mali,Sarah N. Dowey,Donna M. Williams,Yoon Young Jang,Chi V. Dang,Jerry L. Spivak,Alison R. Moliterno,Linzhao Cheng,Linzhao Cheng +11 more
TL;DR: In this article, the authors derived human induced pluripotent stem (iPS) cells from postnatal human blood cells and the potential of these pluripotency cells for disease modeling.
Journal ArticleDOI
Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
TL;DR: Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of MpI or the lack of its expression, and appears to distinguish polycythemia vera from other-forms of erythrocytosis.
Journal ArticleDOI
American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer
J. Douglas Rizzo,Melissa C. Brouwers,Patricia Hurley,Jerome Seidenfeld,Murat O. Arcasoy,Jerry L. Spivak,Charles L. Bennett,Julia Bohlius,Darren Evanchuk,Matthew J. Goode,Ann A. Jakubowski,David H. Regan,Mark R. Somerfield +12 more
TL;DR: Recommendations: ESAs should be avoided in patients with cancer not receiving concurrent chemotherapy, except for those with lower risk myelodysplastic syndromes, and Caution should be exercised when using ESAs with chemotherapeutic agents in diseases associated with increased risk of thromboembolic complications.